Standard BioTools/$LAB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Standard BioTools
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
- Ticker
- $LAB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 387
- Headquarters
- Boston, United States
- Website
- www.standardbio.com
LAB Metrics
BasicAdvanced
$250M
1.86
$0.34
-
-
Price and volume
Market cap
$250M
52-week high
$1.72
52-week low
$0.59
Average daily volume
905K
Financial strength
Current ratio
9.747
Quick ratio
9.292
Long term debt to equity
0.038
Total debt to equity
0.048
Interest coverage (TTM)
-2,953.88%
Profitability
EBITDA (TTM)
-38.092
Gross margin (TTM)
52.18%
Net profit margin (TTM)
157.62%
Operating margin (TTM)
-55.98%
Effective tax rate (TTM)
49.03%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-5.03%
Return on equity (TTM)
-7.79%
Valuation
Price to earnings (TTM)
1.861
Price to revenue (TTM)
2.934
Price to book
0.45
Price to tangible book (TTM)
0.45
Price to free cash flow (TTM)
-3.773
Free cash flow yield (TTM)
-26.50%
Free cash flow per share (TTM)
-0.169
Growth
Revenue change (TTM)
-2.18%
Earnings per share change (TTM)
-200.98%
3-year revenue growth (CAGR)
-7.06%
10-year revenue growth (CAGR)
-2.62%
3-year earnings per share growth (CAGR)
-29.07%
10-year earnings per share growth (CAGR)
-17.92%
What the Analysts think about LAB
Analyst ratings (Buy, Hold, Sell) for Standard BioTools stock.
Analyst projections of the future price of Standard BioTools stock.
LAB Financial Performance
Revenues and expenses
LAB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing LAB
Fund name | Fund size | $LAB weighting |
|---|---|---|
iShares Healthcare Innovation€2B78 | $1.2B | 0.02% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.02% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.